These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 6704155)
1. Inhibition of aromatic amino acid decarboxylase and depletion of biogenic amines in brain of rats treated with alpha-monofluoromethyl p-tyrosine: similitudes and differences with the effects of alpha-monofluoromethyldopa. Jung MJ; Hornsperger JM; Gerhart F; Wagner J Biochem Pharmacol; 1984 Jan; 33(2):327-30. PubMed ID: 6704155 [No Abstract] [Full Text] [Related]
2. Inhibition of monoamine synthesis by irreversible blockade of aromatic aminoacid decarboxylase with alpha-monofluoromethyldopa. Jung MJ; Palfreyman MG; Wagner J; Bey P; Ribereau-Gayon G; Zraïka M; Koch-Weser J Life Sci; 1979 Mar; 24(11):1037-42. PubMed ID: 449607 [No Abstract] [Full Text] [Related]
3. A method for measuring monoamine turnover in animals using an irreversible inhibitor of aromatic L-amino acid decarboxylase, DL-alpha-mono fluoromethyldopa. Palfreyman MG; Zreika M; Arbogast R; Wagner J J Pharmacol Methods; 1984 Jul; 11(4):239-51. PubMed ID: 6204167 [TBL] [Abstract][Full Text] [Related]
4. Monamine-depleting properties of a new and very potent enzyme-activated irreversible inhibitor of aromatic aminoacid decarboxylase: alpha-monofluoromethyldopa [proceedings]. Jung MJ; Palfreyman MG; Ribereau-Gayon G; Wagner J; Zraïka M Br J Pharmacol; 1979 Nov; 67(3):460P. PubMed ID: 497577 [No Abstract] [Full Text] [Related]
5. Further studies on the inhibition of monoamine synthesis by monofluoromethyldopa. Bey P; Jung MJ; Koch-Weser J; Palfreyman MG; Sjoerdsma A; Wagner J; Zraïka M Br J Pharmacol; 1980 Dec; 70(4):571-6. PubMed ID: 7470730 [TBL] [Abstract][Full Text] [Related]
6. Effect of monofluoromethyldopa (MFMD) on trace amine levels. Dyck LE Life Sci; 1987 Feb; 40(6):571-5. PubMed ID: 3807650 [TBL] [Abstract][Full Text] [Related]
7. Irreversible inhibition of aromatic-L-amino acid decarboxylase by alpha-difluoromethyl-DOPA and metabolism of the inhibitor. Ribéreau-Gayon G; Palfreyman MG; Zraïka M; Wagner J; Jung MJ Biochem Pharmacol; 1980 Sep; 29(18):2465-9. PubMed ID: 7426053 [No Abstract] [Full Text] [Related]
8. Use of D,L-alpha-monofluoromethyldopa to distinguish subcellular pools of aromatic amino acid decarboxylase in mouse brain. Gardner CR; Richards MH Brain Res; 1981 Jul; 216(2):291-8. PubMed ID: 6166354 [TBL] [Abstract][Full Text] [Related]
9. Depression of sympathetic nervous function by DL-alpha-monofluoromethyldopa, an enzyme-activated, irreversible inhibitor of L-aromatic amino acid decarboxylase. Fozard JR; Spedding M; Palfreyman MG; Wagner J; Möhring J; Koch-Weser J J Cardiovasc Pharmacol; 1980; 2(3):229-45. PubMed ID: 6156322 [TBL] [Abstract][Full Text] [Related]
10. Effect of decarboxylase inhibitors on brain p-tyrosine levels. Dyck LE Biochem Pharmacol; 1987 Apr; 36(8):1373-6. PubMed ID: 2885004 [TBL] [Abstract][Full Text] [Related]
11. Studies on the depletion of brain amines by m-tyrosine. Smyth RG; Tong JH; D'Iorio A Eur J Pharmacol; 1977 Apr; 42(3):267-73. PubMed ID: 323024 [TBL] [Abstract][Full Text] [Related]
12. Homologs of dopa, alpha-methyldopa, and dopamine as potential cardiovascular drugs. Winn M; Rasmussen R; Minard F; Kyncl J; Plotnikoff N J Med Chem; 1975 Apr; 18(4):434-7. PubMed ID: 1079053 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of peripheral sympathetic function by alpha-monofluoromethyldopa, an irreversible inhibitor of aromatic amino acid decarboxylase [proceedings]. Fozard JR; Palfreyman MG; Spedding M; Wagner J; Woodward JK Br J Pharmacol; 1979 Nov; 67(3):461P. PubMed ID: 497578 [No Abstract] [Full Text] [Related]
14. alpha-difluoromethyl DOPA, a new enzyme-activated irreversible inhibitor of aromatic L-amino acid decarboxylase. Palfreyman MG; Danzin C; Bey P; Jung MJ; Ribereau-Gayon G; Aubry M; Vevert JP; Sjoerdsma A J Neurochem; 1978 Oct; 31(4):927-32. PubMed ID: 308998 [No Abstract] [Full Text] [Related]
15. Studies on the mode of action of alpha-methyldopa. Henning M Acta Physiol Scand Suppl; 1969; 322():1-37. PubMed ID: 4311985 [No Abstract] [Full Text] [Related]
16. Modification of effects of repetitive restraint stress on brain biogenic amines by L-tyrosine. Quirce CM; Odio M; Maickel RP Zhongguo Yao Li Xue Bao; 1984 Dec; 5(4):226-8. PubMed ID: 6240895 [No Abstract] [Full Text] [Related]
17. Modification of the effects of repetitive restraint stress on brain biogenic amines by L-tyrosine. Quirce CM; Odio M; Maickel RP Zhongguo Yao Li Xue Bao; 1984 Dec; 5(4):226-8. PubMed ID: 6242211 [No Abstract] [Full Text] [Related]
18. Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase. Maneckjee R; Baylin SB Biochemistry; 1983 Dec; 22(26):6058-63. PubMed ID: 6661425 [TBL] [Abstract][Full Text] [Related]
19. On suppression of ejaculation by Alpha-methyldopa. Kimura Y; Tadano T; Urano S; Yonezawa A; Watanabe H; Kisara K Andrologia; 1984; 16(2):118-23. PubMed ID: 6742462 [TBL] [Abstract][Full Text] [Related]
20. Inactivation of 3-(3,4-dihydroxyphenyl)alanine decarboxylase by 2-(fluoromethyl)-3-(3,4-dihydroxyphenyl)alanine. Maycock AL; Aster SD; Patchett AA Biochemistry; 1980 Feb; 19(4):709-18. PubMed ID: 7356954 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]